Marie‐Luise Berres, Christian Trautwein, Maximilian Schmeding, Dennis Eurich, Frank Tacke, Marcus Bahra, Peter Neuhaus, Ulf P. Neumann, Hermann E. Wasmuth – 6 December 2010 – The recurrence of liver fibrosis after liver transplantation (LT) for hepatitis C virus (HCV) infection is responsible for graft loss and patient mortality. Although the contribution of the immune system to fibrosis recurrence is anticipated, systematic studies evaluating immune parameters as predictive markers of allograft fibrosis are lacking.

Oyekoya T. Ayonrinde, John K. Olynyk, Lawrence J. Beilin, Trevor A. Mori, Craig E. Pennell, Nicholas de Klerk, Wendy H. Oddy, Peter Shipman, Leon A. Adams – 6 December 2010 – Nonalcoholic fatty liver disease (NAFLD) is a predominantly adult‐diagnosed disorder. Knowledge regarding the epidemiology, phenotype, and metabolic risk factors, during adolescence is limited.

Dennis Eurich, Sabine Boas‐Knoop, Martin Ruehl, Maria Schulz, Esperanza D. Carrillo, Thomas Berg, Ruth Neuhaus, Peter Neuhaus, Ulf Peter Neumann, Marcus Bahra – 6 December 2010 – Up to 30% of liver transplants will develop graft cirrhosis within 5 years after liver transplantation (LT) due to recurrent HCV‐infection forwarding accelerated graft damage. Genetic variants of cytokines involved in the immune response may contribute to the degree of graft inflammation, fibrosis progression, and antiviral therapy outcome.

Christine Gauglhofer, Sandra Sagmeister, Waltraud Schrottmaier, Carina Fischer, Chantal Rodgarkia‐Dara, Thomas Mohr, Stefan Stättner, Christoph Bichler, Daniela Kandioler, Fritz Wrba, Rolf Schulte‐Hermann, Klaus Holzmann, Michael Grusch, Brigitte Marian, Walter Berger, Bettina Grasl‐Kraupp – 6 December 2010 – Fibroblast growth factors (FGFs) and their high‐affinity receptors [fibroblast growth factor receptors (FGFRs)] contribute to autocrine and paracrine growth stimulation in several nonliver cancer entities.

Tomasz Kozlowski, Tara Rubinas, Volker Nickeleit, John Woosley, John Schmitz, Dana Collins, Paul Hayashi, Anthony Passannante, Kenneth Andreoni – 3 December 2010 – The importance of antibody‐mediated rejection (AMR) in ABO‐compatible liver transplantation is controversial. Here we report a prospective series of liver recipients with a preoperative positive crossmatch. To establish the diagnosis of AMR in liver recipients, the criteria described for kidney allografts were adopted.

Philipp Dutkowski, Christian E. Oberkofler, Markus Béchir, Beat Müllhaupt, Andreas Geier, Dimitri A. Raptis, Pierre‐Alain Clavien – 3 December 2010 – We analyzed the first 100 patients who underwent liver transplantation by Model for End‐Stage Liver Disease (MELD) allocation, and compared the outcome of patients on the waiting list and after orthotopic liver transplantation with the last 100 patients who underwent transplantation prior to the introduction of the MELD system in July 2007.

Emmanuel Boleslawski, Samia Ben Othman, Lynda Aoudjehane, Sandrine Chouzenoux, Olivier Scatton, Olivier Soubrane, Yvon Calmus, Nadira Delhem, Filomena Conti – 3 December 2010 – At present, no method is available for accurately monitoring the degree of immunosuppression induced by antirejection therapies. The aim of this study was to determine whether CD28 and CD38 expression by peripheral blood mononuclear cells could be useful in predicting the development of de novo malignancies after liver transplantation.

Dmitri Bezinover, Zakiyah Kadry, Paul McCullough, Patrick M. McQuillan, Todahiro Uemura, Kelli Welker, Andrea M. Mastro, Piotr K. Janicki – 3 December 2010 – The objectives of this prospective, observational study were (1) to determine whether a transplanted liver graft releases proinflammatory cytokines into the systemic circulation upon reperfusion and (2) to determine whether they contribute to any subsequent hemodynamic instability observed after graft reperfusion (if this release occurs).

Ana Moreno, Jesús Fortún, Javier Graus, Miguel A. Rodriguez‐Gandía, Carmen Quereda, María J. Pérez‐Elías, Javier Nuño, Philip Wikman, Santiago Moreno, Rafael Bárcena – 3 December 2010 – Statins are relatively safe first‐line agents to use in the setting of dyslipidemia associated with immunosuppressive therapy in subjects undergoing liver transplantation, and also in HIV‐infected patients with dyslipidemia due to antiretroviral drugs, especially ritonavir‐boosted protease inhibitors.

Shari S. Rogal, Douglas Landsittel, Owen Surman, Raymond T. Chung, Anna Rutherford – 3 December 2010 – Depression is a common problem among patients awaiting organ transplantation, but little is known about the impact of depression and its treatment on the outcomes of liver transplantation. In this retrospective cohort analysis, we studied all patients over 18 years of age who underwent liver transplantation during a 5‐year period (2004‐2008) at a single center. Among 179 recipients, 65 patients had depression, as defined by a health care provider assessment, before transplantation.